CAMP response element binding protein phosphorylation in nucleus accumbens underlies sustained recovery of sensorimotor gating following repeated D 2-like receptor agonist treatment in rats

Biological Psychiatry

Volumn 69, Issue 3, 2011, Pages 288-294

  Berger, Alison K ^a   Green, Thomas ^b   Siegel, Steven J ^c   Nestler, Eric J ^d   Hammer Jr , Ronald P ^a,e,f  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f ARIZONA STATE UNIVERSITY   (United States)

Author keywords

CREB; D2 like receptors; dopamine; prepulse inhibition; quinpirole; ropinirole

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; QUINPIROLE; ROPINIROLE;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CONVALESCENCE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; HUMAN; LONG TERM CARE; MALE; MUTANT; NERVE CELL MEMBRANE POTENTIAL; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SENSORY GATING; TRANSCRIPTION REGULATION;

ADENOVIRIDAE; ANIMALS; CREB-BINDING PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INDOLES; MALE; NEURAL INHIBITION; NUCLEUS ACCUMBENS; PHOSPHORYLATION; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; SENSORY GATING;

EID: 78650802913     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.08.032     Document Type: Article

References (35)

1. D.L. Braff, and M.A. Geyer Sensorimotor gating and schizophrenia Human and animal model studies Arch Gen Psychiatry 47 1990 181 188
2. N.R. Swerdlow, D.L. Braff, N. Taaid, and M.A. Geyer Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients Arch Gen Psychiatry 51 1994 139 154
3. F.J. Wan, and N.R. Swerdlow Intra-accumbens infusion of quinpirole impairs sensorimotor gating of acoustic startle in rats Psychopharmacology 113 1993 103 109
4. R.S. Mansbach, M.A. Geyer, and D.L. Braff Dopaminergic stimulation disrupts sensorimotor gating in the rat Psychopharmacology 94 1988 507 514
5. 2 dopamine receptor agonist disrupts sensorimotor gating in rats Implications for dopaminergic abnormalities in schizophrenia Neuropsychopharmacology 3 1990 211 218
6. N.R. Swerdlow, N. Taaid, J.L. Oostwegel, E. Randolph, and M.A. Geyer Towards a cross-species pharmacology of sensorimotor gating: Effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats Behav Pharmacol 9 1998 389 396
7. J.J. Byrnes, and R.P. Hammer The disruptive effect of cocaine on prepulse inhibition is prevented by repeated administration in rats Neuropsychopharmacology 22 2000 551 554
8. D. Feifel, K. Priebe, E. Johnstone-Miller, and C.J. Morgan Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning Psychopharmacology 162 2002 138 146
9. 2-like dopamine receptor agonist treatment in rats J Pharmacol Exp Ther 308 2004 487 494
10. A.G. Gilman G proteins: Transducers of receptor-generated signals Annu Rev Biochem 56 1987 615 649
11. 2 inhibition and enhances D1 stimulation of adenylate cyclase by dopamine in rat striatum J Neurochem 48 1987 1443 1447
12. V.J. Watts Molecular mechanisms for heterologous sensitization of adenylate cyclase J Pharmacol Exp Ther 302 2002 1 7
13. K.E. Culm, N. Lugo-Escobar, B.T. Hope, and R.P. Hammer Jr Repeated quinpirole treatment increases cAMP-dependent protein kinase activity and CREB phosphorylation in nucleus accumbens and reverses quinpirole-induced sensorimotor gating deficits in rats Neuropsychopharmacology 29 2004 1823 1830
14. K.D. Sethi, C.F. O'Brien, J.P. Hammerstad, C.H. Adler, T.L. Davis, and R.L. Taylor Ropinirole for the treatment of early Parkinson disease: A 12-month experience Ropinirole Study Group Arch Neurol 55 1998 1211 1216
15. 3 receptors Eur J Pharmacol 366 1999 293 300
16. 3) as a target for neuroleptics Nature 347 1990 146 151
17. 3 agonist ropinirole in healthy males Psychopharmacology 194 2007 289 295
18. S.J. Siegel, K.I. Winey, R.E. Gur, R.H. Lenox, W.B. Bilker, and D. Ikeda Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia Neuropsychopharmacology 26 2002 817 823
19. H. Sun, T.A. Green, D.E. Theobald, S.G. Birnbaum, D.L. Graham, and F.D. Zeeb Yohimbine increases impulsivity through activation of cAMP response element binding in the orbitofrontal cortex Biol Psychiatry 67 2010 649 656
20. D.L. Wallace, M.H. Han, D.L. Graham, T.A. Green, V. Vialou, and S.D. Iniguez CREB regulation of nucleus accumbens excitability mediates social isolation-induced behavioral deficits Nat Neurosci 12 2009 200 209
21. G. Paxinos, and C.J. Watson The Rat Brain in Stereotaxic Coordinates 6th ed. 2007 Academic Press New York
22. 2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat Neuropsychopharmacology 12 1995 139 145
23. J.P. Druhan, M.A. Geyer, and R.J. Valentino Lack of sensitization to the effects of d-amphetamine and apomorphine on sensorimotor gating in rats Psychopharmacology 135 1998 296 304
24. S.S. Newton, J. Thome, T.L. Wallace, Y. Shirayama, L. Schlesinger, and N. Sakai Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect J Neurosci 22 2002 10883 10890
25. C.A. McClung, and E.J. Nestler Regulation of gene expression and cocaine reward by CREB and DeltaFosB Nat Neurosci 6 2003 1208 1215
26. W.A. Carlezon Jr, J. Thome, V.G. Olson, S.B. Lane-Ladd, E.S. Brodkin, and N. Hiroi Regulation of cocaine reward by CREB Science 282 1998 2272 2275
27. A.M. Pliakas, R.R. Carlson, R.L. Neve, C. Konradi, E.J. Nestler, and W.A. Carlezon Jr Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens J Neurosci 21 2001 7397 7403
28. J.A. Dinieri, C.L. Nemeth, A. Parsegian, T. Carle, V.V. Gurevich, and E. Gurevich Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens J Neurosci 29 2009 1855 1859
29. 2 interactions regulate prepulse inhibition in rats? Neuropsychopharmacology 14 1996 265 274
30. C. Konradi, and S. Heckers Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia Biol Psychiatry 50 2001 729 742
31. 2 receptor blockade Neuropsychopharmacology 31 2006 1900 1909
32. W. Ondo, C. Hunter, M. Almaguer, S. Gancher, and J. Jankovic Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease Clin Neuropharmacol 22 1999 1 4 (Pubitemid 29161535)
33. D. Tompson, and R. Oliver-Willwong Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease Clin Neuropharmacol 32 2009 140 148
34. B.P. Hersh, N.L. Earl, R.A. Hauser, and M. Stacy Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations Mov Disord 25 2010 927 931
35. M.M. Nashatizadeh, K.E. Lyons, and R. Pahwa A review of ropinirole prolonged release in Parkinson's disease Clin Interv Aging. 4 2009 179 186